⌕
PTC · PTC · Nasdaq
Tenet 62 · Solid
Compare
$196.38+0.19%At closeTenet 62 · Solid
$196.38+0.38 (+0.19%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
$196.30−0.08 (−0.04%)
After hours: Nov 16, 2026, 5:23 PM ET· last 1-minute bar

PTC News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is PTC's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● MarketBeatNov 16, 2026 · 19:17 ETEARNINGS EXPECTED BY FEB 18
PTC Therapeutics Sees $2 Billion-Plus Sephience Potential, Sets January Guidance Date

PTC Therapeutics NASDAQ: PTCT expects to provide 2027 sales guidance for its oral phenylketonuria treatment Sephience in January, as executives seek to convince investors that the drug's strong first year of sales can be…

PTC +0.2% todayRead at source ↗
● Defense WorldNov 16, 2026 · 03:59 ETEARNINGS EXPECTED BY FEB 18
PTC Inc. $PTC Position Lifted by Fisher Asset Management LLC

Fisher Asset Management LLC raised its position in shares of PTC Inc. (NASDAQ: PTC) by 7.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. T…

PTC +0.2% todayRead at source ↗
● GlobeNewsWireNov 11, 2026 · 11:05 ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR)

BALA CYNWYD, Pa., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith…

PTC +0.2% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 08:00 ET
Eos SENOLYTIX's PTC-2105 Reduced Semaglutide-Associated Lean-Mass Loss in Aged Mice: Data to Be Presented at 19th Sarcopenia, Cachexia & Wasting Disorders International Conference

Data to highlight PTC-2105's attenuation of terminal lean-mass decline and semaglutide-associated lean-mass loss in aged mice PTC-2105 is Eos's lead clinical candidate in development for elderly patients with Sarcopenia …

PTC +0.2% todayRead at source ↗
● Business WireNov 7, 2026 · 10:23 ET
PTC Stock Alert: Halper Sadeh LLC is Investigating Whether PTC Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of PTC Inc. (NASDAQ: PTC) to Schneider Electric for $205.00 per share in cash.Halper Sadeh encourages PTC shareholders t…

PTC +0.2% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 15:01 ETEARNINGS EXPECTED BY FEB 18
PTC Inc. (PTC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for PTC Inc. (PTC) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street es…

PTC +0.2% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 12:36 ETEARNINGS EXPECTED BY FEB 18
PTC Q4 Earnings & Revenues Beat Estimates, ARR Growth Strong

PTC's Q4 fiscal 2026 earnings and revenues beat estimates, while ARR growth remain strong despite revenue declines and divestiture-related pressures.…

PTC +0.2% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 18:16 ETEARNINGS EXPECTED BY FEB 18
PTC Inc. (PTC) Surpasses Q4 Earnings and Revenue Estimates

PTC Inc. (PTC) came out with quarterly earnings of $2.03 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $3.47 per share a year ago.…

PTC +0.2% todayRead at source ↗
● PRNewsWireNov 4, 2026 · 16:01 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 18
PTC ANNOUNCES FOURTH FISCAL QUARTER AND FULL FISCAL YEAR 2026 RESULTS

Strategic focus on Intelligent Product Lifecycle vision BOSTON, Nov. 4, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today reported financial results for its fourth fiscal quarter and full fiscal year ended September 30, 2026.…

PTC +0.2% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 08:14 ET
INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – OPCH, PTC, RXO and SYNA - IS IT A FAIR DEAL FOR YOU?

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a …

PTC +0.2% todayRead at source ↗
● PRNewsWireNov 3, 2026 · 19:06 ET
Are OPCH, PTC, RXO Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws…

PTC +0.2% todayRead at source ↗
● Seeking AlphaNov 3, 2026 · 11:31 ETEARNINGS EXPECTED BY FEB 18
PTC Therapeutics: Sephience Keeps Beating The Forecast, But The Price Already Knows

PTC Therapeutics (PTCT) is rated Hold, bordering on Sell, with fair value estimated at $52/share versus a $59.97 current price. Sephience's strong launch drives growth, but legacy product declines offset gains; Q4 and 20…

PTC +0.2% todayRead at source ↗
● PRNewsWireNov 3, 2026 · 07:00 ETCOMPANY'S OWN WORDS
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program

WARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500 million of…

PTC +0.2% todayRead at source ↗
● Zacks Investment ResearchNov 2, 2026 · 09:15 ETEARNINGS EXPECTED BY FEB 18
PTC Heads Into Q4 Earnings as Schneider Buyout Looms: What's in Store?

PTC's fiscal Q4 results hinge on ARR growth, AI adoption and cash flow momentum, while its pending $22.6 billion acquisition by Schneider Electric adds a key dimension.…

PTC +0.2% todayRead at source ↗
● PRNewsWireNov 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
PTC Therapeutics to Participate in Upcoming Investor Conferences

WARREN, N.J., Nov. 2, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Jefferies Global Healthcare Conference  Monday, Nov. 16 at 11 …

PTC +0.2% todayRead at source ↗
● PRNewsWireOct 30, 2026 · 16:30 ETCOMPANY'S OWN WORDS
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of 9.620 shares of its co…

PTC +0.2% todayRead at source ↗
● GlobeNewsWireOct 30, 2026 · 09:36 ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR)

BALA CYNWYD, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith…

PTC +0.2% todayRead at source ↗
● GlobeNewsWireOct 30, 2026 · 08:00 ETEARNINGS EXPECTED BY FEB 18
Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study

Interim Results in Super-Aged Rats Tested Externally Show Preserved Motor Performance and Reduced Fat Mass, Consistent with Prior Findings in Aged Mice Tested at Eos's R&D Facility; Data Support IND-Enabling Development …

PTC +0.2% todayRead at source ↗
● MarketBeatOct 29, 2026 · 21:15 ETEARNINGS EXPECTED BY FEB 18
PTC Therapeutics Q3 Earnings Call Highlights

PTC Therapeutics NASDAQ: PTCT reported third-quarter 2026 total revenue of $358 million, including $276 million in net product revenue, as sales of phenylketonuria treatment Sephience continued to expand in the United St…

PTC +0.2% todayRead at source ↗
● PRNewsWireOct 29, 2026 · 16:01 ETEARNINGS EXPECTED BY FEB 18
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with full-year product revenue gui…

PTC +0.2% todayRead at source ↗
● Zacks Investment ResearchOct 28, 2026 · 11:06 ETEARNINGS EXPECTED BY FEB 18
Analysts Estimate PTC Inc. (PTC) to Report a Decline in Earnings: What to Look Out for

PTC Inc. (PTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

PTC +0.2% todayRead at source ↗
● GlobeNewsWireOct 22, 2026 · 08:00 ET
Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived Mouse

In naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142) “Speedy,” a PTC-2105-trea…

PTC +0.2% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 18. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA9−4.1%
UAL4+1.3%
AMZN3−3.0%
DUOT3−7.1%

Article counts from the last market-wide feed page, across every symbol we track and not just PTC · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.